NO2723977T3 - - Google Patents

Info

Publication number
NO2723977T3
NO2723977T3 NO12802846A NO12802846A NO2723977T3 NO 2723977 T3 NO2723977 T3 NO 2723977T3 NO 12802846 A NO12802846 A NO 12802846A NO 12802846 A NO12802846 A NO 12802846A NO 2723977 T3 NO2723977 T3 NO 2723977T3
Authority
NO
Norway
Application number
NO12802846A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54145440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2723977(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2723977T3 publication Critical patent/NO2723977T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01Q—ANTENNAS, i.e. RADIO AERIALS
    • H01Q1/00—Details of, or arrangements associated with, antennas
    • H01Q1/27—Adaptation for use in or on movable bodies
    • H01Q1/28—Adaptation for use in or on aircraft, missiles, satellites, or balloons
    • H01Q1/288—Satellite antennas
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01Q—ANTENNAS, i.e. RADIO AERIALS
    • H01Q1/00—Details of, or arrangements associated with, antennas
    • H01Q1/36—Structural form of radiating elements, e.g. cone, spiral, umbrella; Particular materials used therewith
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01Q—ANTENNAS, i.e. RADIO AERIALS
    • H01Q5/00—Arrangements for simultaneous operation of antennas on two or more different wavebands, e.g. dual-band or multi-band arrangements
    • H01Q5/50—Feeding or matching arrangements for broad-band or multi-band operation
    • H01Q5/55—Feeding or matching arrangements for broad-band or multi-band operation for horn or waveguide antennas
NO12802846A 2014-03-19 2012-04-16 NO2723977T3 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461955299P 2014-03-19 2014-03-19

Publications (1)

Publication Number Publication Date
NO2723977T3 true NO2723977T3 (el) 2018-03-10

Family

ID=54145440

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12802846A NO2723977T3 (el) 2014-03-19 2012-04-16

Country Status (24)

Country Link
US (2) US9968609B2 (el)
EP (2) EP3119201B1 (el)
JP (1) JP6744821B2 (el)
KR (1) KR20160137584A (el)
CN (1) CN106132204B (el)
AU (2) AU2015233006B2 (el)
CA (1) CA2942628C (el)
CL (1) CL2016002318A1 (el)
CY (1) CY1120187T1 (el)
DK (1) DK3119201T3 (el)
EA (1) EA032819B1 (el)
ES (1) ES2668915T3 (el)
HR (1) HRP20180773T1 (el)
HU (1) HUE038431T2 (el)
IL (1) IL247840B (el)
LT (1) LT3119201T (el)
MX (1) MX371276B (el)
NO (1) NO2723977T3 (el)
PL (1) PL3119201T3 (el)
PT (1) PT3119201T (el)
RS (1) RS57206B1 (el)
SG (2) SG11201607507VA (el)
SI (1) SI3119201T1 (el)
WO (1) WO2015140748A2 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2723977T3 (el) 2014-03-19 2018-03-10
JP6902372B2 (ja) * 2017-02-28 2021-07-14 ヱスビー食品株式会社 苦味抑制用組成物
JP2021509114A (ja) 2017-12-26 2021-03-18 エフティーエフ ファーマ プライベート リミテッド Ｐｄｅ ｖ阻害剤のための液体経口処方物
CA3137260A1 (en) * 2019-04-18 2020-10-22 Ellamed Ip & Services Pte. Ltd. Liquid sildenafil citrate compositions
US20220387433A1 (en) * 2019-11-12 2022-12-08 American Regent, Inc. Type v phosphodiesterase inhibitor compositions, methods of making them and methods of using them in preventing or treating elevated pulmonary vascular pressure or pulmonary hemorrhages

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785984A (en) * 1993-02-05 1998-07-28 Kao Corporation Taste-modifying method and bitterness-decreasing method
CN1065415C (zh) * 1993-02-05 2001-05-09 花王株式会社 蛋白质和类脂复合体用于改善味觉的用途
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
TWI223598B (en) 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
EP1237538A2 (en) * 1999-11-18 2002-09-11 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
WO2001056547A2 (en) 2000-02-04 2001-08-09 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
WO2002005820A1 (en) 2000-07-19 2002-01-24 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
US20030216407A1 (en) 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
US7611728B2 (en) 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
US20070065394A1 (en) 2003-11-17 2007-03-22 Pinney Virginia R Compositions effective in altering the perception of malodor
CN1925860A (zh) * 2004-01-05 2007-03-07 特瓦制药工业有限公司 制备西地那非碱及其柠檬酸盐的方法
WO2005067936A2 (en) 2004-01-05 2005-07-28 Teva Pharmaceutical Industries Ltd. Methods for the production of sildenafil base and citrate salt
US7727565B2 (en) 2004-08-25 2010-06-01 Cadbury Adams Usa Llc Liquid-filled chewing gum composition
GT200600112A (es) 2005-03-14 2006-11-29 Composiciiones de tigeciclina y metodos de preparacion
US7556487B2 (en) 2006-03-29 2009-07-07 Intergum Gida Sinayi ve Ticaret A.S. Apparatus for making center-filled chewing gum pieces
FR2906140B1 (fr) * 2006-09-22 2008-12-05 Philippe Perovitch Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
EP2008530B1 (de) 2007-06-19 2011-01-19 Symrise AG Aromakomposition zum Verringern oder Unterdrücken von unerwünschtem bitteren und adstringierenden Eindruck
EP2072044A1 (en) * 2007-12-19 2009-06-24 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising a liquid or flowable core composition
WO2009125415A1 (en) 2008-04-07 2009-10-15 Hetero Research Foundation Amorphous form of sildenafil citrate
FR2939321B1 (fr) 2008-12-05 2011-08-26 Philippe Perovitch Dispositif de conditionnement et d'administration de principes actifs en solution hydro-alcoolique.
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
DE102010049708A1 (de) * 2010-10-28 2012-05-03 Hexal Ag Orale pharmazeutische Filmformulierung für bitter schmeckende Arzneistoffe
AU2012347997B2 (en) * 2011-12-05 2017-07-20 Suda Limited Oral spray formulations and methods for administration of sildenafil
GB2497933B (en) 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
CA3189252A1 (en) * 2012-05-16 2013-11-21 Techfields Pharma Co., Ltd. High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
NO2723977T3 (el) 2014-03-19 2018-03-10

Also Published As

Publication number Publication date
EA032819B1 (ru) 2019-07-31
SG11201607507VA (en) 2016-10-28
CL2016002318A1 (es) 2017-03-24
EP3372083A1 (en) 2018-09-12
JP2017508764A (ja) 2017-03-30
US20170049776A1 (en) 2017-02-23
EP3119201A4 (en) 2017-03-15
CN106132204B (zh) 2019-08-20
CN106132204A (zh) 2016-11-16
AU2015233006B2 (en) 2018-07-19
SI3119201T1 (en) 2018-07-31
PT3119201T (pt) 2018-06-15
IL247840B (en) 2019-03-31
WO2015140748A3 (en) 2015-12-17
WO2015140748A2 (en) 2015-09-24
CA2942628A1 (en) 2015-09-24
JP6744821B2 (ja) 2020-08-19
HRP20180773T1 (hr) 2018-06-15
CY1120187T1 (el) 2018-12-12
PL3119201T3 (pl) 2018-08-31
MX371276B (es) 2020-01-23
EP3119201A2 (en) 2017-01-25
US9968609B2 (en) 2018-05-15
ES2668915T3 (es) 2018-05-23
AU2015233006A1 (en) 2016-11-03
RS57206B1 (sr) 2018-07-31
AU2018250378A1 (en) 2018-11-08
LT3119201T (lt) 2018-05-10
SG10201808038TA (en) 2018-10-30
KR20160137584A (ko) 2016-11-30
AU2018250378B2 (en) 2020-05-14
US20180233823A1 (en) 2018-08-16
DK3119201T3 (en) 2018-05-28
EA201691871A1 (ru) 2017-03-31
CA2942628C (en) 2022-06-07
HUE038431T2 (hu) 2018-10-29
MX2016012154A (es) 2016-12-15
US10211534B2 (en) 2019-02-19
EP3119201B1 (en) 2018-03-14

Similar Documents

Publication Publication Date Title
BR112014017614A2 (el)
BR112014018528A2 (el)
BR112014017625A2 (el)
BR112014017659A2 (el)
BR112014017646A2 (el)
BR112014017638A2 (el)
AR092201A1 (el)
BR112014017607A2 (el)
BR112013027865A2 (el)
BR112014017609A2 (el)
BR112014017673A2 (el)
BR112014017644A2 (el)
BR112014017647A2 (el)
BR112014018625A2 (el)
BR112014017618A2 (el)
BR112014017652A2 (el)
BR112014017621A2 (el)
BR112014017622A2 (el)
BR112014017623A2 (el)
BR112014023519A2 (el)
BR112014017641A2 (el)
BR112014021331A2 (el)
BR112014017667A2 (el)
BR112014017600A2 (el)
BR112014017768A2 (el)